Project Grant R01FD005077

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $430,375 over 2 years (9/1/2024 - 8/31/2026) to the Mayo Clinic Jacksonville (a nonprofit organization) to explore the role of extracellular vesicles in mediating communication between glioblastoma (GBM) cells and the tumor microenvironment, specifically within the subventricular...

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established...

This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $402,401 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to evaluate the role of SPAK and OSR1 kinases in glioblastoma (GBM) chemotherapy resistance. The 2-year project, running from July 2024 to June 2026, aims to assess if these stress-sensing kinases serve as a resistance mechanism to standard-of-care chemoradiotherapy for GBM, the most deadly brain cancer. The research...

Federal Grant Award Summary Nuvox Pharma, L.L.C. received a $1.84 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on September 22, 2025, with an ultimate completion date of August 31, 2027. The award supports the development and validation of liquid biopsy biomarkers as a diagnostic tool for glioblastoma (GBM) patients undergoing chemoradiation therapy combined with dodecafluoropentane emulsion (DDFPE), an...

Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $548,395 to the Beckman Research Institute of the City of Hope under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on May 1, 2026. This five-year Project Grant, extending through April 30, 2031, supports research targeting glioblastoma (GBM) through the development and optimization of multifunctional anti-Receptor for Advanced...

Summary The National Cancer Institute awarded a $659,201 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) under the Cancer Treatment Research program (CFDA 93.395) with an award date of June 1, 2026 and completion date of May 30, 2031. The research initiative investigates the Integrated Stress Response (ISR) in glioblastoma (GBM) pathogenesis and therapeutic response, focusing on how tumor cells, particularly glioma stem cells (GSCs), adapt to survive stress...

Summary The National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) awarded a $683,970 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) beginning April 1, 2026, with completion targeted for March 31, 2031. This award supports research aimed at modifying the pancreatic cancer tumor microenvironment through the αvβ5 integrin pathway. The research focuses on developing and evaluating the IRGD tumor-penetrating peptide as a...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $472,124 to Beth Israel Deaconess Medical Center, Inc. to conduct exploratory studies on the role of TREM1 and TREM2 receptors in the immune response to glioblastoma, an aggressive form of brain cancer. The research aims to use a novel mouse model of glioblastoma to investigate how...

Federal Grant Award Summary Glycyx Mor, Inc. received a $1.197 million Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 19, 2025, to conduct a Phase 2 clinical trial evaluating axelopran plus pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with PD-L1 CPS >1. The research will test whether the addition of axelopran, a peripherally-restricted opioid...